omeprazole has been researched along with exenatide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bahekar, R; Detroja, J; Dhanesha, N; Dhote, V; Gandhi, T; Jain, M; Joharapurkar, A; Kshirsagar, S; Patel, K; Patel, V | 1 |
| Bahekar, R; Detroja, J; Dhanesha, N; Gandhi, T; Jain, M; Joharapurkar, A; Kshirsagar, S; Patel, K; Patel, V | 1 |
1 review(s) available for omeprazole and exenatide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for omeprazole and exenatide
| Article | Year |
|---|---|
Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.
Topics: Animals; Anti-Obesity Agents; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Gastrins; Glucagon; Hypoglycemic Agents; Insulin Resistance; Leptin; Male; Mice; Mice, Inbred Strains; Mice, Obese; Obesity; Omeprazole; Peptides; Venoms | 2013 |
Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Liver; Male; Mice; NF-E2-Related Factor 2; Omeprazole; Peptides; Proton Pump Inhibitors; Venoms | 2013 |